Horizon Pharma (HZNP) Stock Rating Lowered by BidaskClub

Horizon Pharma (NASDAQ:HZNP) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other equities research analysts have also issued reports on the company. Jefferies Group upped their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target on shares of Horizon Pharma in a research note on Sunday, October 22nd. Mizuho raised Horizon Pharma from a “neutral” rating to a “buy” rating and increased their price target for the stock from $12.00 to $18.00 in a research note on Friday, January 12th. ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Monday, October 16th. Finally, Cantor Fitzgerald set a $17.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.25.

Shares of Horizon Pharma (HZNP) opened at $14.99 on Tuesday. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $17.69. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $2,460.00, a P/E ratio of -4.93, a P/E/G ratio of 0.68 and a beta of 1.30.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. During the same quarter in the prior year, the company earned $0.70 EPS. Horizon Pharma’s revenue was up 30.1% on a year-over-year basis. equities analysts forecast that Horizon Pharma will post 0.72 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of HZNP. Paulson & CO. Inc. purchased a new position in shares of Horizon Pharma in the 2nd quarter worth $58,584,000. Dimensional Fund Advisors LP raised its position in shares of Horizon Pharma by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after buying an additional 3,409,411 shares during the period. Ameriprise Financial Inc. raised its position in shares of Horizon Pharma by 419.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock worth $26,979,000 after buying an additional 1,717,841 shares during the period. Balyasny Asset Management LLC purchased a new position in shares of Horizon Pharma in the 2nd quarter worth $13,958,000. Finally, State Street Corp raised its position in shares of Horizon Pharma by 12.0% in the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after buying an additional 524,187 shares during the period. 86.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://stocknewstimes.com/2018/01/18/horizon-pharma-hznp-stock-rating-lowered-by-bidaskclub.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply